CurisCRIS
CRIS
0
Funds holding %
of 7,390 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
900% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 1
367% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 3
29% more funds holding
Funds holding: 31 [Q3] → 40 (+9) [Q4]
4.21% more ownership
Funds ownership: 33.74% [Q3] → 37.95% (+4.21%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
10% less capital invested
Capital invested by funds: $10.9M [Q3] → $9.84M (-$1.04M) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for CRIS.
Financial journalist opinion
Neutral
PRNewsWire
3 months ago
Curis Announces Additional Data from TakeAim Leukemia Study
LEXINGTON, Mass. , Dec. 10, 2024 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, yesterday presented data from the TakeAim Leukemia study (CA-4948-102) in relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) at the 66th ASH annual meeting.

Neutral
Seeking Alpha
4 months ago
Curis, Inc. (CRIS) Q3 2024 Earnings Call Transcript
Curis, Inc. (NASDAQ:CRIS ) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Diantha Duvall - Chief Financial Officer Jim Dentzer - President & Chief Executive Officer Jonathan Zung - Chief Development Officer Conference Call Participants Ed White - H.C. Wainwright Billal Jahangiri - Truist Securities Daniel Bronder - Cantor Sean McCutcheon - Raymond James Operator Good morning, ladies and gentlemen, and welcome to the Curis Third Quarter 2024 Business Update Call.

Negative
Zacks Investment Research
4 months ago
Curis (CRIS) Reports Q3 Loss, Tops Revenue Estimates
Curis (CRIS) came out with a quarterly loss of $1.70 per share versus the Zacks Consensus Estimate of a loss of $1.88. This compares to loss of $2.13 per share a year ago.

Neutral
PRNewsWire
4 months ago
Curis Provides Third Quarter 2024 Business Update
Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass.

Neutral
PRNewsWire
4 months ago
Curis to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on November 14, 2024
LEXINGTON, Mass. , Nov. 7, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its third quarter 2024 financial and operating results on Thursday, November 14, 2024, at 8:00 a.m.

Neutral
PRNewsWire
4 months ago
Curis Announces $12.1 Million Registered Direct and Concurrent Private Placement
LEXINGTON, Mass. , Oct. 29, 2024 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that it has entered into a definitive agreement with a combination of existing and new investors for the purchase of 2,398,414 shares of its common stock in a registered direct offering priced at-the-market under Nasdaq rules.

Neutral
PRNewsWire
6 months ago
Curis Announces the 3rd Annual Symposium on IRAK4 in Cancer
Symposium hosted by Eric S. Winer, MD, and Grzegorz S.

Neutral
PRNewsWire
6 months ago
Curis to Participate at the Upcoming 2024 Cantor Fitzgerald Global Healthcare Conference
LEXINGTON, Mass. , Sept. 17, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate in a fireside chat at the 2024 Cantor Fitzgerald Global Healthcare Conference later today at 4:15 PM ET.

Neutral
PRNewsWire
6 months ago
Curis to Present at Upcoming Healthcare Conferences in September
LEXINGTON, Mass. , Sept. 4, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate at the following conferences: The H.C.

Neutral
Seeking Alpha
7 months ago
Curis, Inc. (CRIS) Q2 2024 Earnings Call Transcript
Curis, Inc. (NASDAQ:CRIS ) Q2 2024 Earnings Conference Call August 1, 2024 8:30 AM ET Company Participants Diantha Duvall - Chief Financial Officer Jim Dentzer - President and CEO Jonathan Zung - Chief Development Officer Conference Call Participants Yale Jen - Laidlaw Ed White - H.C. Wainwright Soumit Roy - JonesTrading Li Watsek - Cantor Operator Good morning, ladies and gentlemen.

Charts implemented using Lightweight Charts™